Literature DB >> 9566807

Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test.

M Bourin1, J P Redrobe, G B Baker.   

Abstract

The present study was undertaken to identify the receptor subtypes involved in (+/-) pindolol's ability to enhance the effects of antidepressant drugs in the mouse forced swimming test. Interaction studies were performed with S 15535 (presynaptic 5-HT1A receptor agonist) and methiothepin (5-HT1B autoreceptor antagonist) in an attempt to attenuate or potentiate antidepressant-like activity. (+/-) Pindolol was tested in combination with selective agonists and antagonists at 5-HT1, 5-HT2 and 5-HT3 receptor subtypes. Pretreatment with S 15535 and methiothepin attenuated the activity of paroxetine, fluvoxamine and citalopram (32 mg/kg, i.p.; P < 0.01). (+/-) Pindolol (32 mg/kg, i.p.) induced significant anti-immobility effects when tested in combination with 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridyl)-1H-indole (RU 24969) (1 mg/kg, i.p.; P < 0.05), 1-(2-methoxyphenyl)-4-[-(2-phthalimido) butyl]piperazine) (NAN 190) (0.5 mg/kg; P < 0.05) and ondansetron (0.00001 mg/kg, i.p.; P < 0.01). Pretreatment with NAN 190 (0.5 mg/kg, i.p.) potentiated the effects of RU 24969 (1 mg/kg, i.p.; P < 0.05) and (+/-) pindolol (32 mg/kg, i.p.; P < 0.05) in the forced swimming test, as did ondansetron (0.00001 mg/kg, i.p.). Significant additive effects were induced when RU 24969 (1 mg/kg, i.p.) was tested in combination with NAN 190 (0.5 mg/kg, i.p.; P < 0.05), (+/-) pindolol (32 mg/kg, i.p.; P < 0.05) and ondansetron (0.0000 mg/kg, i.p.; P < 0.05). 8-Hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) (1 mg/kg, i.p.) or ketanserin (8 mg/kg, i.p.) did not induce significant antidepressant-like effects with any of the agonists/antagonists tested. The results of the present study suggest that pindolol is acting at presynaptic 5-HT1B serotonergic receptors, in addition to the 5-HT1A subtype, in augmenting the activity of antidepressants in the mouse forced swimming test.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566807     DOI: 10.1007/s002130050560

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test.

Authors:  Michel Bourin; Fabienne Masse; Martine Hascoët
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

2.  Factors producing a menopausal depressive-like state in mice following ovariectomy.

Authors:  Naoko Bekku; Hiroyuki Yoshimura; Hiroaki Araki
Journal:  Psychopharmacology (Berl)       Date:  2006-06-21       Impact factor: 4.530

Review 3.  Paroxetine: a review.

Authors:  M Bourin; P Chue; Y Guillon
Journal:  CNS Drug Rev       Date:  2001

4.  Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: a microdialysis study.

Authors:  L A Dawson; H Q Nguyen; D I Smith; L E Schechter
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

5.  Acute effects of combining citalopram and pindolol on regional brain serotonin synthesis in sham operated and olfactory bulbectomized rats.

Authors:  Khanh Q Nguyen; Yoshihiro Tohyama; Arata Watanabe; Shu Hasegawa; Ivan Skelin; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-27       Impact factor: 3.921

6.  Paroxetine combined with a 5-HT(1A) receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats.

Authors:  Athina Markou; Amanda A Harrison; Jessica Chevrette; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

7.  Dissecting the roles of β-arrestin2 and GSK-3 signaling in 5-HT1BR-mediated perseverative behavior and prepulse inhibition deficits in mice.

Authors:  Summer L Thompson; Stephanie C Dulawa
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

8.  5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders.

Authors:  Shvetank Bhatt; Thangaraj Devadoss; Santhepete Nanjundaiah Manjula; Jayaraman Rajangam
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.